Sodium Carbonate → Phenylmethyl (2S)-4-({2'-fluoro-5'-[({[3-(4-piperidinyl)phenyl]carbonyl}amino)methyl]-3-biphenylyl}methyl)-2-methyl-1-piperazinecarboxylate

HRID 2080325ノート

反応式

HRID 2080325 の反応式
CC(OC([N:8]1[CH2:13][CH2:12][CH:11]([C:14]2[CH:15]=[C:16]([CH:20]=[CH:21][CH:22]=2)[C:17]([OH:19])=O)[CH2:10][CH2:9]1)=O)(C)C.[NH2:23][CH2:24][C:25]1[CH:26]=[CH:27][C:28]([F:55])=[C:29]([C:31]2[CH:36]=[CH:35][CH:34]=[C:33]([CH2:37][N:38]3[CH2:43][CH2:42][N:41]([C:44]([O:46][CH2:47][C:48]4[CH:53]=[CH:52][CH:51]=[CH:50][CH:49]=4)=[O:45])[C@@H:40]([CH3:54])[CH2:39]3)[CH:32]=2)[CH:30]=1.CCN(C(C)C)C(C)C.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.C([O-])([O-])=O.[Na+].[Na+]>CN(C=O)C.CCOC(C)=O>[F:55][C:28]1[CH:27]=[CH:26][C:25]([CH2:24][NH:23][C:17]([C:16]2[CH:20]=[CH:21][CH:22]=[C:14]([CH:11]3[CH2:10][CH2:9][NH:8][CH2:13][CH2:12]3)[CH:15]=2)=[O:19])=[CH:30][C:29]=1[C:31]1[CH:36]=[CH:35][CH:34]=[C:33]([CH2:37][N:38]2[CH2:43][CH2:42][N:41]([C:44]([O:46][CH2:47][C:48]3[CH:53]=[CH:52][CH:51]=[CH:50][CH:49]=3)=[O:45])[C@@H:40]([CH3:54])[CH2:39]2)[CH:32]=1

参加物

8

反応物 5

HCID 10340Sodium CarbonateHCID 81531DiisopropylethylamineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 450737913-(1-(tert-Butoxycarbonyl)piperidin-4-yl)benzoic acidHCID 57730446Phenylmethyl (2S)-4-{[5'-(aminomethyl)-2'-fluoro-3-biphenylyl]methyl}-2-methyl-1-piperazinecarboxylate

生成物 1

HCID 57736691Phenylmethyl (2S)-4-({2'-fluoro-5'-[({[3-(4-piperidinyl)phenyl]carbonyl}amino)methyl]-3-biphenylyl}methyl)-2-methyl-1-piperazinecarboxylate収率 43%

試薬・触媒・溶媒 2

HCID 6228Dimethylformamide溶媒HCID 8857Ethyl Acetate溶媒

実験手順

To a solution of the commercially available 3-(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)benzoic acid (183 mg, 0.60 mmol) in 2 mL of dry DMF was added phenylmethyl (2S)-4-{[5′-(aminomethyl)-2′-fluoro-3-biphenylyl]methyl}-2-methyl-1-piperazinecarboxylate (250 mg, 0.60 mmol), DIPEA (0.2 ml, 1.4 mmol), and HATU (251 mg, 0.66 mmol). The reaction mixture was stirred at room temperature for 2 h before addition of 2 mL of saturated Na2CO3 and 10 mL of EtOAc. The organic layer was separated, dried over Na2SO4, and filtered. The filtrate was concentrated and the residue was mixed with 4M HCl in 1,4-dioxane (5 mL). The resulting mixture was stirred at room temperature for 1 h. After removal of the solvent, the residue was purified by Gilson reverse phase HPLC, eluting with acetonitrile/water/0.1% TFA (10/90 to 70/30, v/v, over 12 min), to give the title compound (162 mg, 43%). LC/MS: m/z, 635 (M+H), 1.75 min.

後処理

  1. customThe organic layer was separated
  2. dry with materialdried over Na2SO4
  3. filtrationfiltered
  4. concentrationThe filtrate was concentrated
  5. additionthe residue was mixed with 4M HCl in 1,4-dioxane (5 mL)
  6. customAfter removal of the solvent
  7. customthe residue was purified by Gilson reverse phase HPLC
  8. washeluting with acetonitrile/water/0.1% TFA (10/90 to 70/30, v/v, over 12 min)

出典と根拠

ORDレコード
ord-62c1683a158041a183376bf0584bc667
出典データセット
uspto-grants-2011_04
特許番号
US07932247B2

反応ノート

読み込み中…